The Experts below are selected from a list of 579 Experts worldwide ranked by ideXlab platform

Kartik S Jhaveri - One of the best experts on this subject based on the ideXlab platform.

  • impact of mri technique on clinical decision making in patients with liver iron overload comparison of ferriscan versus r2 derived liver iron concentration
    European Radiology, 2020
    Co-Authors: Marshall S Sussman, Richard Ward, Kevin H M Kuo, George Tomlinson, Kartik S Jhaveri
    Abstract:

    The purpose of this study was to compare clinical decision-making in iron overload patients using FerriScan and an R2*-based approach. One-hundred and six patients were imaged at two consecutive timepoints (454 ± 158 days) on a 1.5-T Siemens MAGNETOM Avanto Fit scanner. For both timepoints, patients underwent the standard FerriScan MRI protocol. During the second exam, each patient additionally underwent R2*-MRI mapping. For each patient, a retrospective (simulated) decision was made to increase, decrease, or maintain chelator levels. Two different decision models were considered: The fixed threshold model assumed that chelator adjustments are based strictly on fixed liver iron concentration (LIC) thresholds. Decisions made with this model depend only on the most recent LIC value and do not require any clinician input. The second model utilized decisions made by two hematologists retrospectively based on trends between two consecutive LIC values. Agreement (κA) between hematologists (i.e., interobserver variability) was compared with the agreement (κB) between a single hematologist using the two different LIC techniques. Good agreement between R2*- and FerriScan-derived decisions was achieved for the fixed threshold model. True positive/negative rates were greater than 80%, and false positive/negative rates were less than 10%. ROC analysis yielded areas under the curve greater than 0.95. In the second model, the agreement in clinical decision-making for the two scenarios (κA vs. κB) was equal at the 95% confidence level. Switching to R2*-based LIC estimation from FerriScan has the same level of agreement in patient management decisions as does switching from one hematologist to another. • Good agreement between R2*- and FerriScan-derived decisions in liver iron overload patient management • Switching to R2*-based LIC estimation from FerriScan has the same level of agreement in patient management decisions as does switching from one hematologist to another.

  • consensus statements from a multidisciplinary expert panel on the utilization and application of a liver specific mri contrast agent gadoxetic acid
    American Journal of Roentgenology, 2015
    Co-Authors: Kartik S Jhaveri, Sean P Cleary, Pascale Audet, Fady Balaa, Deepak Bhayana, Kelly W Burak, Silvia D Chang, Elijah Dixon, Masoom A Haider, Michele Molinari
    Abstract:

    OBJECTIVE. This systematic review presents evidence-based consensus statements as reported by a multidisciplinary expert panel (six abdominal radiologists, four hepatobiliary surgeons, and two Hepatologists) regarding the use of gadoxetic acid for liver MRI. CONCULSION. Although this review highlights the incremental diagnostic value of hepatobiliary phase imaging with gadoxetic acid-enhanced liver MRI in multiple clinical scenarios, there remains a need for further impact studies for some clinical applications, such as hepatocellular carcinoma in cirrhosis.

Denise M Adams - One of the best experts on this subject based on the ideXlab platform.

  • vascular anomaly cases for the pediatric hematologist oncologists an interdisciplinary review
    Pediatric Blood & Cancer, 2018
    Co-Authors: Denise M Adams, Leonardo R. Brandão, Caitlin M. Peterman, Anita Gupta, Manish N. Patel, Steven J. Fishman, Cameron C. Trenor
    Abstract:

    Vascular anomalies (VAs) are classified as tumors or malformations depending on their clinical characteristics, pathological diagnosis, and genomic information. Diagnosis can be challenging because of the heterogeneity of clinical presentation; thus, the best diagnosis and care are provided by an interdisciplinary team of specialists. Over the past 10 years, an increasing number of pediatric hematologist/oncologists are caring for patients with VAs secondary to new medical therapy options and clinical trials. This paper focuses on complicated VA issues often seen by the pediatric hematologist/oncologist. The paper reviews clinical pearls on diagnosis, histology, radiology, and treatment options.

  • the role of the hematologist oncologist in the care of patients with vascular anomalies
    Pediatric Clinics of North America, 2008
    Co-Authors: Denise M Adams, Mary Sue Wentzel
    Abstract:

    Pediatric hematologist/oncologists have a critical role in the diagnosis and management of patients who have complex vascular anomalies. They provide the clinical and medical skills needed to diagnose, treat, and manage these patients. Hematologist/oncologists also provide support for clinical trials and drug development to further treatment options for these patients.

Alfredo Guarino - One of the best experts on this subject based on the ideXlab platform.

Mary Sue Wentzel - One of the best experts on this subject based on the ideXlab platform.

Kathleen Viveiros - One of the best experts on this subject based on the ideXlab platform.

  • hepatology consultants often disagree on etiology of abnormal liver biochemistries in covid 19 but agree on management
    Digestive Diseases and Sciences, 2021
    Co-Authors: Patricia P Bloom, Trisha Pasricha, Karin L Andersson, Daniel S Pratt, Nikroo Hashemi, Irun Bhan, Kathleen Viveiros
    Abstract:

    Coronavirus disease 2019 (COVID-19) is associated with elevated liver biochemistries in approximately half of hospitalized patients, with many possible etiologies. To assess agreement on the etiology of abnormal liver biochemistries and diagnostic recommendations in COVID-19. Twenty hepatology consultations were reviewed by three senior Hepatologists who provided a differential diagnosis and diagnostic recommendations. Kappa agreement on the primary etiology was calculated. Kappa agreement between Hepatologists on the primary etiology of elevated liver biochemistries was 0.10 (p = 0.03). Agreement was greater around drug-induced liver injury 0.51 (p < 0.0001) and SARS-CoV-2-related liver injury 0.17 (p = 0.03). Serial liver biochemistries were recommended in all consultations over other evaluations. In COVID-19, elevated liver biochemistries present a diagnostic challenge and can often be monitored conservatively.